Where Globus Medical Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the last quarter, Globus Medical (NYSE:GMED) received indifferent ratings from three analysts. The company's average 12-month price target is $63.67, an increase of 1.06% from the previous average price target of $63.00.
August 04, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Globus Medical received indifferent ratings from three analysts in the last quarter. The average 12-month price target is $63.67, up 1.06% from the previous target.
The indifferent ratings from analysts suggest that they do not see any significant short-term price movement for Globus Medical. The slight increase in the average price target could indicate a potential upside, but it's not significant enough to suggest a strong bullish sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100